Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Nasal challenge with allergen leads to maxillary sinus inflammation

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Pru p 3 acts as a strong sensitizer for peanut allergy in Spain

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Allergen immunotherapy: A practice parameter third update

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Clarification concerning amoxicillin skin testing

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy Michael Kulis, PhD, Katie.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Role of the basophil activation test in the diagnosis of local allergic rhinitis Enrique Gómez, PhD, Paloma Campo, MD, PhD, Carmen Rondón, MD, PhD, Esther.

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Major rabbit allergen Ory c 3: What could be its possible role as a sensitizing agent in real life? Gennaro Liccardi, MD, Antonello Salzillo, MD, Maria.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison Danilo Di.

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis Mitsuhiro Okano, MD, Tazuko Fujiwara, BS, Takaya.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis Carmen Rondón, MD, PhD, Paloma Campo,

T-cell involvement in delayed-type hypersensitivity reactions to infliximab Maria Jose Torres, MD, PhD, Patrícia Chaves, PhD, Inmaculada Doña, MD, Natalia.

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions Maria José Torres, MD, PhD,

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Reply The Journal of Allergy and Clinical Immunology: In Practice

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation Abel Suárez-Fueyo, PhD, Tania.

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Children's compliance with allergen immunotherapy according to administration routes Giovanni Battista Pajno, MD, Daniela Vita, MD, Lucia Caminiti, MD,

What is an “eosinophilic phenotype” of asthma?

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis Sriram Vaidyanathan, MBBS, Peter Williamson,

House dust mite sublingual immunotherapy: Results of a US trial

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis Karl-Christian Bergmann, MD, Pascal Demoly,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

The National Institutes of Allergy and Infectious Diseases networks on asthma in inner- city children: An approach to improved care William W. Busse,

Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis Carmen Rondón, MD, PhD, Javier.

Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis

Thunderstorm-related asthma attacks

Nasal challenge with allergen leads to maxillary sinus inflammation

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Macrolide antibiotics and asthma treatment

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Role of Art v 3 in pollinosis of patients allergic to Pru p 3

Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison Janine Dretzke, MSc, Angela Meadows,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Immediate allergic reactions to cephalosporins: Evaluation of cross-reactivity with a panel of penicillins and cephalosporins Cristina Antunez, PhD,

Presentation transcript:

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia Blanca-López, MD, PhD, Ana Aranda, BS, Rocío Herrera, BSN, José Luis Rodriguez-Bada, BS, Gabriela Canto, MD, PhD, Cristobalina Mayorga, PhD, María José Torres, MD, PhD, Paloma Campo, MD, Miguel Blanca, MD, PhD Journal of Allergy and Clinical Immunology Volume 127, Issue 4, Pages 1069-1071.e7 (April 2011) DOI: 10.1016/j.jaci.2010.12.013 Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Tolerance to grass pollen after specific SCIT. Journal of Allergy and Clinical Immunology 2011 127, 1069-1071.e7DOI: (10.1016/j.jaci.2010.12.013) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Rhinoconjunctivitis symptoms and use of rescue medication after treatment with specific SCIT (SCIT group) and rescue medication (control group). A, Symptom score. B, Rescue medication score. C, Rescue medication–free days. Gray bars, Baseline evaluation; black bars, 1 year after. Data are shown as medians and SEMs. P values refer to comparisons between values for the SCIT and control groups (Mann-Whitney U test). Journal of Allergy and Clinical Immunology 2011 127, 1069-1071.e7DOI: (10.1016/j.jaci.2010.12.013) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Evolution of serum levels of sIgG to Lolium and Phleum species pollen and changes from baseline to 12 months after initiation of treatment. Serum levels of Lolium species (A and B) and Phleum species (C and D) sIgG (mean ± SEM) at baseline and 1, 3, 6, and 12 months after beginning the study are shown. Solid line, SCIT group; dotted line, control group. P values refer to comparisons between baseline values and values 12 months after initiation of treatment (Wilcoxon test). Journal of Allergy and Clinical Immunology 2011 127, 1069-1071.e7DOI: (10.1016/j.jaci.2010.12.013) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Evolution of serum levels of sIgE to Lolium and Phleum species pollen and changes from baseline to 12 months after initiation of treatment. Serum levels of Lolium species (A and B) and Phleum species (C and D) sIgE (mean ± SEM) at baseline and 1, 3, 6, and 12 months after beginning the study are shown. Solid line, SCIT group; dotted line, control group. Journal of Allergy and Clinical Immunology 2011 127, 1069-1071.e7DOI: (10.1016/j.jaci.2010.12.013) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Severity of LAR after specific SCIT Severity of LAR after specific SCIT. White bars, Mild rhinitis; gray bars, moderate rhinitis; black bars, severe rhinitis. Data are shown as percentages of patients. Journal of Allergy and Clinical Immunology 2011 127, 1069-1071.e7DOI: (10.1016/j.jaci.2010.12.013) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions